摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,11-O,O-bridged erythromycin A 9-oxime 9,2',4"-triacetate | 625389-97-1

中文名称
——
中文别名
——
英文名称
6,11-O,O-bridged erythromycin A 9-oxime 9,2',4"-triacetate
英文别名
[(2S,3R,4S,6R)-2-[[(1R,2R,3R,6R,7S,8S,9R,10R,16S,17E,18R)-17-acetyloxyimino-7-[(2R,4R,5S,6S)-5-acetyloxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3-ethyl-2-hydroxy-2,6,8,10,16,18-hexamethyl-13-methylidene-5-oxo-4,11,15-trioxabicyclo[8.5.4]nonadecan-9-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl] acetate
6,11-O,O-bridged erythromycin A 9-oxime 9,2',4"-triacetate化学式
CAS
625389-97-1
化学式
C47H78N2O16
mdl
——
分子量
927.14
InChiKey
UXCHWVUOQPQZLC-VZFALDHPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    65
  • 可旋转键数:
    13
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.85
  • 拓扑面积:
    206
  • 氢给体数:
    1
  • 氢受体数:
    18

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6,11-O,O-bridged erythromycin A 9-oxime 9,2',4"-triacetate盐酸sodium periodate四氧化锇 、 titanium(III) chloride 作用下, 以 四氢呋喃乙醇二氯甲烷丙酮 为溶剂, 反应 2.0h, 生成
    参考文献:
    名称:
    有效的大规模合成EDP-420,一流的桥接双环大环内酯(BBM)抗生素候选药物
    摘要:
    描述了新型桥联双环大环内酯候选药物EDP-420(1)的多步骤,实用且经济高效的合成方法。从廉价且可商购的红霉素A 9-肟开始,当前的化学过程涉及一系列转化:三乙酰化,Pd催化的O,O-双-烯丙基化(桥形成),酸催化的糖裂解,肟还原,乙酰化, Os催化桥烯烃氧化裂解,Corey-Kim氧化,桥肟形成,脱保护和最终纯化。多千克量已合成。
    DOI:
    10.1021/op900228u
  • 作为产物:
    参考文献:
    名称:
    有效的大规模合成EDP-420,一流的桥接双环大环内酯(BBM)抗生素候选药物
    摘要:
    描述了新型桥联双环大环内酯候选药物EDP-420(1)的多步骤,实用且经济高效的合成方法。从廉价且可商购的红霉素A 9-肟开始,当前的化学过程涉及一系列转化:三乙酰化,Pd催化的O,O-双-烯丙基化(桥形成),酸催化的糖裂解,肟还原,乙酰化, Os催化桥烯烃氧化裂解,Corey-Kim氧化,桥肟形成,脱保护和最终纯化。多千克量已合成。
    DOI:
    10.1021/op900228u
点击查看最新优质反应信息

文献信息

  • [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES KETOLIDES BICYCLIQUES 6-11
    申请人:ENANTA PHARM INC
    公开号:WO2005061525A1
    公开(公告)日:2005-07-07
    The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    本发明公开了具有以下结构的化合物,或其药学上可接受的盐、酯或前药:(I),这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物,用于给需要抗生素治疗的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
  • [EN] 6-11 BICYCLIC KETOLIDE DRIVATIVES<br/>[FR] DERIVES DE KETOLIDE 6-11 BICYCLIQUES
    申请人:ENANTA PHARM INC
    公开号:WO2005061526A1
    公开(公告)日:2005-07-07
    The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    本发明公开了具有以下结构的化合物I,或其药学上可接受的盐、酯或前药:Formule (I),其具有抗菌性能。本发明还涉及包括上述化合物的药物组合物,用于给需要抗生素治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
  • Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182
    申请人:Xu Guoyou
    公开号:US20070207972A1
    公开(公告)日:2007-09-06
    The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine:
    本发明涉及用于制备被称为EDP-182(IX-a)的6-11环式红霉素生物的过程和中间体。具体而言,本发明涉及用于制备O-(2-基苯并[d]噁唑-5-基)甲基羟胺的过程和中间体。
  • [EN] PROCESS FOR THE PREPARATION OF T-11 BICYCLIC ERYTHROMYCIN DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES BICYCLIQUES 6-11 D'ERYTHROMYCINE
    申请人:ENANTA PHARM INC
    公开号:WO2005070918A1
    公开(公告)日:2005-08-04
    The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivatives. In particular, the presen tinvention relates to processes and intermediates for the preparation of a compound of formula (IX-c).
    本发明涉及用于制备6-11双环红霉素生物的过程和中间体。具体而言,本发明涉及用于制备化合物(IX-c)的过程和中间体。
  • Synthesis of Novel 6,11-O-Bridged Bicyclic Ketolides via a Palladium-Catalyzed Bis-allylation
    作者:Guoqiang Wang、Deqiang Niu、Yao-Ling Qiu、Ly Tam Phan、Zhigang Chen、Alexander Polemeropoulos、Yat Sun Or
    DOI:10.1021/ol048336r
    日期:2004.11.1
    A bridging chemistry process was developed to form an ether bridge between 6-O and 11-O of erythromycin A via a tandem or stepwise palladium-catalyzed bis-pi-allylation. By applying this bridging process, new 6,11-O-bridged bicyclic ketolides (BBKs) were synthesized. These BBKs showed good antibacterial activities against the macrolide-susceptible strains as well as mef-resistant strains and served as a good core for further modifications to study the structure-activity relationship (SAR) and to overcome bacterial resistance.
查看更多